SciSparc Enrolls First 5 Patients in SCI-210 Trial
Ticker: SPRC · Form: 6-K · Filed: Aug 20, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Aug 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, enrollment, drug-development
TL;DR
SciSparc just enrolled 5 patients in their SCI-210 trial. Big step forward.
AI Summary
SciSparc Ltd. announced on August 19, 2024, that it has enrolled the first five patients in its clinical trial for SCI-210. This marks a significant step in the development of their innovative treatment.
Why It Matters
The enrollment of the first patients is a crucial milestone for SciSparc, indicating progress in their clinical development program for SCI-210, which could lead to new treatment options.
Risk Assessment
Risk Level: medium — Clinical trial progress is a positive development, but the success of the trial and subsequent regulatory approval are not guaranteed.
Key Numbers
- 5 — Patients Enrolled (First patients enrolled in the SCI-210 clinical trial.)
Key Players & Entities
- SciSparc Ltd. (company) — Registrant
- SCI-210 (drug_candidate) — Treatment being trialed
- August 19, 2024 (date) — Date of press release
FAQ
What is the specific indication for the SCI-210 treatment being tested?
The filing does not specify the indication for the SCI-210 treatment.
What is the total number of patients planned for the SCI-210 clinical trial?
The filing does not state the total number of patients planned for the trial.
When was the press release announcing the enrollment issued?
The press release was issued on August 19, 2024.
What is SciSparc Ltd.'s principal executive office address?
SciSparc Ltd.'s principal executive office is located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel.
Is SciSparc Ltd. required to file annual reports on Form 20-F?
Yes, SciSparc Ltd. indicated it files annual reports under cover of Form 20-F.
Filing Stats: 338 words · 1 min read · ~1 pages · Grade level 8.8 · Accepted 2024-08-20 07:00:19
Filing Documents
- ea0211738-6k_scisparc.htm (6-K) — 13KB
- ea021173802ex99-1_scisparc.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-070903.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: August 20, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3